All Stories

ImmuneOnco axes CD47 bispecific as pipeline prioritization pressures hit Chinese biotech

ImmuneOnco Biopharmaceuticals has shown Chinese biotechs are far from immune to the pressures to prioritize pipelines. Eighteen months after listing in Hong Kong, the biotech has stopped development of two clinical programs and abandoned plans to build a manufacturing facility.

Mar 27, 2025 - 23:12
 0
ImmuneOnco axes CD47 bispecific as pipeline prioritization pressures hit Chinese biotech
ImmuneOnco Biopharmaceuticals has shown Chinese biotechs are far from immune to the pressures to prioritize pipelines. Eighteen months after listing in Hong Kong, the biotech has stopped development of two clinical programs and abandoned plans to build a manufacturing facility.
Read More

Tags:

Previous Article

Wave's DMD drug remains on track in 48-week data ahead of FDA push next year

Next Article

Acrivon stops developing Lilly castoff for ovarian and bladder cancers to switch...

Related Posts

Paragonix's donor kidney perfusion system completes commercial flight

Paragonix's donor kidney perfusion system completes com...

Mar 3, 2025  0

J&J's Shockwave Medical launches path-clearing Javelin lithotripsy catheter

J&J's Shockwave Medical launches path-clearing Javelin ...

Mar 6, 2025  0

Pfizer, Flagship tap Valo Health for autoimmune offshoot of multibillion-dollar collab

Pfizer, Flagship tap Valo Health for autoimmune offshoo...

Apr 1, 2025  0